SCHOLAR ROCK HOLDING CORP (SRRK) Stock Price, Quote, News and Overview
NASDAQ:SRRK - Nasdaq - US80706P1030 - Common Stock - Currency: USD
SRRK Quote, Performance and Key Statistics
NASDAQ:SRRK (8/12/2025, 1:30:00 PM)
32.17
+0.71 (+2.26%)
The current stock price of SRRK is 32.17 USD. In the past month the price decreased by -18.48%. In the past year, price increased by 237.55%.
SRRK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.73 | 350.33B | ||
| AMGN | AMGEN INC | 13.03 | 152.79B | ||
| GILD | GILEAD SCIENCES INC | 15.45 | 148.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 98.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.18 | 60.01B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.08B | ||
| ARGX | ARGENX SE - ADR | 69.4 | 39.37B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.59B | ||
| INSM | INSMED INC | N/A | 22.86B | ||
| NTRA | NATERA INC | N/A | 22.04B | ||
| BIIB | BIOGEN INC | 8.07 | 18.94B |
Related stock screener links
About SRRK
Company Profile
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2018-05-24. The firm is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.
Company Info
SCHOLAR ROCK HOLDING CORP
301 Binney Street, 3rd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Stuart A. Kingsley
Employees: 128
Phone: 18572593860
SCHOLAR ROCK HOLDING CORP / SRRK FAQ
What is the stock price of SCHOLAR ROCK HOLDING CORP today?
The current stock price of SRRK is 32.17 USD. The price increased by 2.26% in the last trading session.
What is the ticker symbol for SCHOLAR ROCK HOLDING CORP stock?
The exchange symbol of SCHOLAR ROCK HOLDING CORP is SRRK and it is listed on the Nasdaq exchange.
On which exchange is SRRK stock listed?
SRRK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCHOLAR ROCK HOLDING CORP stock?
16 analysts have analysed SRRK and the average price target is 53.33 USD. This implies a price increase of 65.78% is expected in the next year compared to the current price of 32.17. Check the SCHOLAR ROCK HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCHOLAR ROCK HOLDING CORP worth?
SCHOLAR ROCK HOLDING CORP (SRRK) has a market capitalization of 3.05B USD. This makes SRRK a Mid Cap stock.
How many employees does SCHOLAR ROCK HOLDING CORP have?
SCHOLAR ROCK HOLDING CORP (SRRK) currently has 128 employees.
What are the support and resistance levels for SCHOLAR ROCK HOLDING CORP (SRRK) stock?
SCHOLAR ROCK HOLDING CORP (SRRK) has a support level at 31.39 and a resistance level at 40.08. Check the full technical report for a detailed analysis of SRRK support and resistance levels.
Should I buy SCHOLAR ROCK HOLDING CORP (SRRK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRRK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRRK, evaluating the profitability, health, valuation and growth aspects
- SCHOLAR ROCK HOLDING CORP (SRRK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCHOLAR ROCK HOLDING CORP (SRRK) Sales and EPS estimates to see what analysts future expectations are.
- SCHOLAR ROCK HOLDING CORP (SRRK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCHOLAR ROCK HOLDING CORP (SRRK) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCHOLAR ROCK HOLDING CORP (SRRK) Stock Chart to make your own analysis
- SCHOLAR ROCK HOLDING CORP (SRRK) Latest news and press-releases to stay up to date.
Does SCHOLAR ROCK HOLDING CORP (SRRK) stock pay dividends?
SRRK does not pay a dividend.
When does SCHOLAR ROCK HOLDING CORP (SRRK) report earnings?
SCHOLAR ROCK HOLDING CORP (SRRK) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of SCHOLAR ROCK HOLDING CORP (SRRK)?
SCHOLAR ROCK HOLDING CORP (SRRK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.92).
What is the Short Interest ratio of SCHOLAR ROCK HOLDING CORP (SRRK) stock?
The outstanding short interest for SCHOLAR ROCK HOLDING CORP (SRRK) is 15.69% of its float. Check the ownership tab for more information on the SRRK short interest.
SRRK Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK is one of the better performing stocks in the market, outperforming 97.57% of all stocks.
SRRK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRRK. SRRK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SRRK Financial Highlights
Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS decreased by -31.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.82% | ||
| ROE | -84.58% | ||
| Debt/Equity | 0.16 |
SRRK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to SRRK. The Buy consensus is the average rating of analysts ratings from 16 analysts.